Non-Alcoholic Fatty Liver Disease Clinical Trials in San Antonio, Texas

5 studies are recruiting for non-alcoholic fatty liver disease in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

    Stage
    Phase 3
    Ages
    18 to 75
    Site
    GSK Investigational Site, San Antonio, Texas
    Locations
    66 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT07221188 on ClinicalTrials.gov

  2. Quantifying Hepatic Mitochondrial Fluxes in Humans

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    Stage
    Phase 4
    Ages
    18 to 80
    Site
    Texas Diabetes Institute - University Health System, San Antonio, Texas
    Locations
    2 in total
    Run by
    The University of Texas Health Science Center at San Antonio

    See if you can join NCT05305287 on ClinicalTrials.gov

  3. A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

    Stage
    Phase 3
    Ages
    18 to 75
    Site
    GSK Investigational Site, San Antonio, Texas
    Locations
    91 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT07221227 on ClinicalTrials.gov

  4. A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    GSK Investigational Site, San Antonio, Texas
    Locations
    30 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT06920043 on ClinicalTrials.gov

  5. A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

    This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    GSK Investigational Site, San Antonio, Texas
    Locations
    3 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT07358546 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.